X Cahu1, C Bodet-Milin2, E Brissot1, H Maisonneuve3, R Houot4, N Morineau5, P Solal-Celigny6, P Godmer7, T Gastinne1, P Moreau1, A Moreau8, T Lamy9, F Kraber-Bodere10, S Le Gouill11. 1. Department of Hematology. 2. Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes. 3. Department of Hematology, Centre Hospitalier Départemental La Roche-sur-Yon. 4. Department of Hematology, Hôpital Pontchaillou, Centre Hospitalier Universitaire Rennes, Rennes. 5. Department of Hematology, Centre Catherine de Sienne, Nantes. 6. Department of Hematology and Oncology, Centre Jean Bernard, Clinique Victor Hugo, Le Mans. 7. Department of Hematology, Centre Hospitalier Départemental Vannes, Vannes. 8. Department of Pathology, Centre Hospitalier Universitaire Nantes, Nantes. 9. Department of Hematology, Hôpital Pontchaillou, Centre Hospitalier Universitaire Rennes, Rennes; Research Unit, Inserm U917, Université de Rennes I, Rennes. 10. Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes; Center for Oncology Research Nantes/Angers, Inserm UMR 892, Nantes; Department of Nuclear Medicine, Centre René Gauducheau, Saint-Herblain. 11. Department of Hematology; Center for Oncology Research Nantes/Angers, Inserm UMR 892, Nantes; Center for Clinical Investigation in Oncology (CI2C), Centre Hospitalier Universitaire Nantes, France. Electronic address: steven.legouill@chu-nantes.fr.
Abstract
BACKGROUND: In non-cutaneous T-cell/natural killer (T/NK) lymphomas, the prognostic value of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) during or after therapy is unknown. PATIENTS AND METHODS: In this retrospective study, 54 T/NK lymphoma patients were assessed using FDG-PET before (n = 40), during (n = 44) and/or after therapy (n = 31). RESULTS: FDG-PET showed an abnormal FDG uptake in all cases. Interim FDG-PET was negative in 25 of 44 cases. After completion of therapy, 19 of 31 patients reached complete remission with negative FDG-PET. In ALK+ anaplastic large cell lymphomas, the 4-year progression-free survival (PFS) was 80% and the negative predictive value of post-therapy FDG-PET was 83% (n = 9). In ALK- T/NK lymphomas, the 4-year PFS was 59% for patients with a negative interim FDG-PET versus 46% for patients with a positive interim FDG-PET (P = 0.28, n = 35). Similarly, there was no statistical difference in 4-year PFS between negative and positive post-therapy FDG-PET in these lymphomas (51% and 67%, respectively, P = 0.96). The 4-year cumulative incidence of relapse from a negative post-therapy FDG-PET was 53% in ALK- T/NK lymphomas. CONCLUSIONS: Although T/NK lymphomas are FDG-avid at diagnosis, a negative interim or post-therapy FDG-PET does not translate into an improved PFS in ALK- T/NK lymphomas.
BACKGROUND: In non-cutaneous T-cell/natural killer (T/NK) lymphomas, the prognostic value of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) during or after therapy is unknown. PATIENTS AND METHODS: In this retrospective study, 54 T/NK lymphomapatients were assessed using FDG-PET before (n = 40), during (n = 44) and/or after therapy (n = 31). RESULTS:FDG-PET showed an abnormal FDG uptake in all cases. Interim FDG-PET was negative in 25 of 44 cases. After completion of therapy, 19 of 31 patients reached complete remission with negative FDG-PET. In ALK+ anaplastic large cell lymphomas, the 4-year progression-free survival (PFS) was 80% and the negative predictive value of post-therapy FDG-PET was 83% (n = 9). In ALK- T/NK lymphomas, the 4-year PFS was 59% for patients with a negative interim FDG-PET versus 46% for patients with a positive interim FDG-PET (P = 0.28, n = 35). Similarly, there was no statistical difference in 4-year PFS between negative and positive post-therapy FDG-PET in these lymphomas (51% and 67%, respectively, P = 0.96). The 4-year cumulative incidence of relapse from a negative post-therapy FDG-PET was 53% in ALK- T/NK lymphomas. CONCLUSIONS: Although T/NK lymphomas are FDG-avid at diagnosis, a negative interim or post-therapy FDG-PET does not translate into an improved PFS in ALK- T/NK lymphomas.
Authors: John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544